PKB: Early Covid-19 treatments
"Plandemic" Knowledge Base Topic
“COVID-19 VACCINE DAMAGE REPAIR PROTOCOL” (Dave’s Newsletter):
“Degradative Effect of Nattokinase on Spike Protein of SARS-CoV-2” (Molecules, 2022.08.24):
When cell lysates transfected with S protein were incubated with nattokinase, the S protein was degraded in a dose- and time-dependent manner. Immunofluorescence analysis showed that S protein on the cell surface was degraded when nattokinase was added to the culture medium. Thus, our findings suggest that nattokinase exhibits potential for the inhibition of SARS-CoV-2 infection via S protein degradation.
“Regular use of ivermectin as prophylaxis for COVID-19 led up to 92% reduction in COVID-19 mortality rate in a dose-response manner: results of a prospective observational study of a strictly controlled population of 88,012 subjects among 223,128 participants” (ResearchGate Preprint, July 2022):
There were 0 COVID hospitalizations in the group of regular ivermectin users compared to 10 in the irregular user group.
“Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients” (Future Microbiol., 2022.06.13):
In 24 COVID-19 subjects refusing hospitalization with high-risk features, hypoxia and untreated moderate to severe symptoms averaging 9 days, the authors administered this novel combination of ivermectin, doxycycline, zinc and vitamins D and C.
Results & conclusions: All subjects resolved symptoms (in 11 days on average), and oxygen saturation improved in 24 h (87.4% to 93.1%; p = 0.001). There were no hospitalizations or deaths, less than (p < 0.002 or 0.05, respectively) background-matched CDC database controls. Triple combination therapy is safe and effective even when used in outpatients with moderate to severe symptoms.
“Dr. Peter McCullough Protocol: Hydroxychloroquine and Home Treatment for COVID-19” (Dr. Peter McCullough, 2022.04.25)
“Vitamin D Status & SARS-CoV-2 Infection & COVID-19 Clinical Outcomes” (Dr. Paul Alexander, 2022.01.17): “To reduce the risk of infection, it is recommended that people at risk of influenza and/or COVID-19 consider taking 10,000 IU/d of vitamin D3 for a few weeks to rapidly raise 25(OH)D concentrations, followed by 5000 IU/d. The goal should be to raise 25(OH)D concentrations above 40-60 ng/mL (100-150 nmol/L). For treatment of people who become infected with COVID-19, higher vitamin D3 doses might be useful.“
“COVID-19 Mortality Risk Correlates Inversely with Vitamin D3 Status, and a Mortality Rate Close to Zero Could Theoretically Be Achieved at 50 ng/mL 25(OH)D3: Results of a Systematic Review and Meta-Analysis” (PubMed, 2021.10.14): “Conclusions: The datasets provide strong evidence that low D3 is a predictor rather than just a side effect of the infection. Despite ongoing vaccinations, we recommend raising serum 25(OH)D levels to above 50 ng/mL to prevent or mitigate new outbreaks due to escape mutations or decreasing antibody activity.“
In the present study, we characterized in detail the nuclear transport inhibitory properties of ivermectin, demonstrating that it is a broad-spectrum inhibitor of importin α/β nuclear import, with no effect on a range of other nuclear import pathways, including that mediated by importin β1 alone. Importantly, we establish for the first time that ivermectin has potent antiviral activity towards both HIV-1 and dengue virus, both of which are strongly reliant on importin α/β nuclear import, with respect to the HIV-1 integrase and NS5 (non-structural protein 5) polymerase proteins respectively. Ivermectin would appear to be an invaluable tool for the study of protein nuclear import, as well as the basis for future development of antiviral agents.
FLCCC Alliance - Front Line COVID-19 Critical Care Alliance: Prevention & Treatment Protocols for COVID-19
Dr. Zelenko’s Z Stack Protocol (VIDEO)
“Early treatment book is now available on Amazon” (Steve Kirsch, 2022.01.09)
“POVIDONE-IODINE/betadine nasal/oral wash” as a prophylaxis and early treatment (Dr. Paul Alexander, 2022.01.12)
Enter your suggestions in the comments section below.